These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36921770)

  • 21. Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.
    Antoine D; Huhn AS; Strain EC; Turner G; Jardot J; Hammond AS; Dunn KE
    Am J Addict; 2021 Jan; 30(1):83-87. PubMed ID: 32572978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
    Piske M; Zhou H; Min JE; Hongdilokkul N; Pearce LA; Homayra F; Socias ME; McGowan G; Nosyk B
    Addiction; 2020 Aug; 115(8):1482-1493. PubMed ID: 31899565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Buprenorphine/naloxone induction in a Canadian emergency department with rapid access to community-based addictions providers.
    Hu T; Snider-Adler M; Nijmeh L; Pyle A
    CJEM; 2019 Jul; 21(4):492-498. PubMed ID: 31006398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone.
    Kline A; Williams JM; Steinberg ML; Mattern D; Chesin M; Borys S; Chaguturu V
    J Subst Use Addict Treat; 2023 Jun; 149():209028. PubMed ID: 37003539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial.
    Bahji A; Bastien G; Bach P; Choi J; Le Foll B; Lim R; Jutras-Aswad D; Socias ME
    Can J Psychiatry; 2024 Mar; 69(3):172-182. PubMed ID: 37697811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
    Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H
    Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developing A Rapid Transfer from Opioid Full Agonist to Buprenorphine: "Ultrarapid Micro-Dosing" Proof of Concept.
    Azar P; Mathew N; Mahal D; Wong JSH; Westenberg JN; Schütz CG; Greenwald MK
    J Psychoactive Drugs; 2023; 55(1):94-101. PubMed ID: 35152847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series.
    Shearer D; Young S; Fairbairn N; Brar R
    Drug Alcohol Rev; 2022 Feb; 41(2):444-448. PubMed ID: 34647379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.
    Romero-Gonzalez M; Shahanaghi A; DiGirolamo GJ; Gonzalez G
    Am J Addict; 2017 Dec; 26(8):838-844. PubMed ID: 29143399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
    Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
    Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
    Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
    Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient opinion and acceptance of emergency department buprenorphine/naloxone to-go home initiation packs.
    Duncan K; Scheuermeyer F; Lane D; Ahamad K; Moe J; Dong K; Nolan S; Buxton J; Miles I; Johnson C; Christenson J; Whyte M; Daoust R; Garrod E; Badke K; Kestler A
    CJEM; 2023 Oct; 25(10):802-807. PubMed ID: 37606738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion.
    Saloner B; Levin J; Chang HY; Jones C; Alexander GC
    JAMA Netw Open; 2018 Aug; 1(4):e181588. PubMed ID: 30646116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.
    Bach P; Bawa M; Grant C; Milloy MJ; Hayashi K
    Int J Drug Policy; 2022 Mar; 101():103545. PubMed ID: 34875527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.
    Socias ME; Wood E; Le Foll B; Lim R; Choi JC; Mok WY; Bruneau J; Rehm J; Wild TC; Bozinoff N; Hassan A; Jutras-Aswad D;
    Addiction; 2022 Oct; 117(10):2662-2672. PubMed ID: 35712892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of selection into buprenorphine/naloxone among people initiating opioid agonist treatment in British Columbia.
    Homayra F; Hongdilokkul N; Piske M; Pearce LA; Zhou H; Min JE; Krebs E; Nosyk B
    Drug Alcohol Depend; 2020 Feb; 207():107798. PubMed ID: 31927163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
    Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
    Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada.
    Iacono A; Wang T; Tadrous M; Campbell T; Kolla G; Leece P; Sproule B; Kleinman RA; Besharah J; Munro C; Doolittle M; Gomes T
    Drug Alcohol Depend; 2024 Jan; 254():111032. PubMed ID: 38043224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
    Saulle R; Vecchi S; Gowing L
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing characteristics and outcomes of different opioid agonist treatment modalities among opioid-dependent federal men correctional populations in Canada.
    Farrell MacDonald S; Russell C; Beauchamp T; Derkzen D; Fischer B
    Int J Drug Policy; 2022 Feb; 100():103480. PubMed ID: 34656817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.